{
  "kind": "treatment",
  "slug": "alprazolam-xanax",
  "type": "anxiolytic",
  "name": "Alprazolam (Xanax)",
  "summary": "A short-acting benzodiazepine commonly prescribed for anxiety and panic disorders.",
  "description": "Alprazolam is a triazolobenzodiazepine that enhances the effects of the inhibitory neurotransmitter GABA by binding to the benzodiazepine site on the GABA-A receptor complex. It is primarily used for generalized anxiety disorder (GAD) and panic disorder, and is known for its rapid onset of action.",
  "category": "medications/anxiolytics",
  "tags": [
    "benzodiazepine",
    "anxiety",
    "panic-disorder",
    "sedative"
  ],
  "metadata": {
    "drug_classes": [
      "Benzodiazepine",
      "Anxiolytic",
      "Sedative-Hypnotic"
    ],
    "therapeutic_categories": [
      "Anxiety Disorders",
      "Panic Disorder"
    ],
    "mechanism_categories": [
      "GABA"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": true,
    "brand_names": [
      "Xanax",
      "Niravam"
    ],
    "dea_schedule": "IV",
    "fda_pregnancy_category": "D",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary Care",
      "Internal Medicine"
    ],
    "fda_approval_year": 1981
  },
  "clinical_metadata": {
    "primary_indications": [
      "Anxiety"
    ],
    "off_label_uses": [
      "Depression (adjunct)",
      "Premenstrual Syndrome",
      "Insomnia (short-term)"
    ],
    "contraindications": [
      "Acute narrow-angle glaucoma",
      "Concurrent ketoconazole or itraconazole use",
      "Known hypersensitivity to benzodiazepines"
    ],
    "monitoring_required": [
      "Signs of dependence and misuse",
      "Sedation level",
      "Respiratory status in high-risk patients"
    ],
    "efficacy_rating": {
      "anxiety": 5,
      "panic-disorder": 5,
      "overall_tolerability": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "alprazolam",
      "xanax",
      "benzodiazepine",
      "panic attack",
      "anxiety medication"
    ],
    "synonyms": [
      "triazolobenzodiazepine"
    ],
    "common_misspellings": [
      "alprazolam",
      "zanax",
      "xannax"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Generalized Anxiety Disorder (GAD)",
        "Panic Disorder",
        "Short-term relief of anxiety symptoms"
      ]
    },
    {
      "type": "mechanism",
      "text": "Binds to the benzodiazepine site on the GABA-A receptor complex, increasing the frequency of chloride channel opening and enhancing inhibitory neurotransmission."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "0.25–0.5 mg two to three times daily",
        "titrate": "Increase by no more than 1 mg/day at 3–4 day intervals as needed",
        "usual_range": "0.5–4 mg/day in divided doses",
        "max": "10 mg/day (rarely used clinically)"
      },
      "geriatric": "Start 0.25 mg two to three times daily; titrate cautiously",
      "hepatic_impairment": "Use lower starting doses and monitor closely",
      "renal_impairment": "Use with caution"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg",
        "Orally disintegrating tablets",
        "Extended-release tablets: 0.5 mg, 1 mg, 2 mg, 3 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within 30–60 minutes; duration of effect 4–6 hours (IR) or up to 11 hours (XR)."
    },
    {
      "type": "adverse_effects",
      "common": [
        "drowsiness",
        "fatigue",
        "impaired coordination",
        "memory impairment"
      ],
      "less_common": [
        "depression",
        "confusion",
        "constipation",
        "dry mouth"
      ],
      "serious": [
        "respiratory depression",
        "severe dependence and withdrawal",
        "paradoxical reactions (e.g., agitation)"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.",
      "other": [
        "Risk of dependence, abuse, and withdrawal",
        "Avoid abrupt discontinuation to prevent withdrawal symptoms and seizures"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Opioids",
          "risk": "Respiratory depression, sedation, death",
          "action": "Avoid or monitor closely"
        },
        {
          "with": "CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)",
          "risk": "↑ alprazolam levels",
          "action": "Contraindicated"
        },
        {
          "with": "Alcohol or other CNS depressants",
          "risk": "Additive sedation and respiratory depression",
          "action": "Avoid"
        },
        {
          "with": "CYP3A4 inducers (e.g., carbamazepine, rifampin)",
          "risk": "↓ alprazolam levels",
          "action": "May require dose adjustment"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Signs of misuse, abuse, and dependence",
        "Sedation level",
        "Respiratory rate in at-risk patients",
        "Mental status and coordination"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Category D; avoid unless benefits outweigh fetal risks.",
      "lactation": "Excreted in breast milk; avoid or monitor infant for sedation.",
      "pediatrics": "Not routinely recommended; dosing individualized if used.",
      "geriatrics": "Use lowest effective dose to minimize sedation and fall risk."
    },
    {
      "type": "tapering",
      "text": "Reduce dose gradually by 0.25–0.5 mg every 3–7 days; taper more slowly in long-term users."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Short-term use preferred due to dependence potential.",
        "Extended-release formulations may improve adherence in panic disorder.",
        "Avoid in patients with a history of substance use disorder unless benefits clearly outweigh risks."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "FDA Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "APA Guidelines for Anxiety Disorders",
          "url": "https://psychiatry.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Alprazolam (Xanax): Dosing, Side Effects, Interactions",
    "description": "Comprehensive guide to alprazolam, including dosing, onset, side effects, and precautions."
  }
}
